(Q44282746)

1 December 2017

title

The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients (English)

1 reference

1 December 2017

1 reference

0 references

1 reference

2

1 reference

1 December 2017

1

Jensen-Fangel S

1 reference

1 December 2017

5

Obel N

1 reference

1 December 2017

Black FT

3

1 reference

1 December 2017

Pedersen C

series ordinal

4

1 reference

1 December 2017

publication date

1 January 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

4

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

48-52

1 reference

Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

21 January 2018

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Management of protease inhibitor-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Safety, tolerability, and antiretroviral effects of ritonavir-nelfinavir combination therapy administered for 48 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Diarrhea in patients with the acquired immunodeficiency syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

Pharmacokinetic enhancement of protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2003.00135.X

10.1046/J.1468-1293.2003.00135.X

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference